HTL0041178 (), a potent GPR52 agonist with a promising pharmacokinetic profile and exhibiting oral activity in preclinical models, has been identified. This molecule was the outcome of a judicious molecular property-based optimization approach, focusing on balancing potency against metabolic stability, solubility, permeability, and P-gp efflux.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107915 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.3c00052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice.
Transl Psychiatry
September 2024
Preclinical Laboratory, Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic and University of Zurich, Zurich, Switzerland.
Reward processing dysfunctions e.g., anhedonia, apathy, are common in stress-related neuropsychiatric disorders including depression and schizophrenia, and there are currently no established therapies.
View Article and Find Full Text PDFDiscovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.
J Med Chem
June 2024
Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Orphan GPR52 is emerging as a promising neurotherapeutic target. Optimization of previously reported lead employing an iterative drug design strategy led to the identification of a series of unique GPR52 agonists, such as (), (), and (), with improved potency and efficacy. Intriguingly, compounds and showed greater bias for G protein/cAMP signaling and induced significantly less in vitro desensitization than parent compound , indicating that reducing GPR52 β-arrestin activity with biased agonism results in sustained GPR52 activation.
View Article and Find Full Text PDFOrphan GPR52 as an emerging neurotherapeutic target.
Drug Discov Today
April 2024
Chemical Biology Program, Department of Pharmacology and Toxicology, and Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address:
GPR52 is a highly conserved, brain-enriched, G-coupled orphan G protein-coupled receptor (GPCR) that controls various cyclic AMP (cAMP)-dependent physiological and pathological processes. Stimulation of GPR52 activity might be beneficial for the treatment of schizophrenia, psychiatric disorders and other human neurological diseases, whereas inhibition of its activity might provide a potential therapeutic approach for Huntington's disease. Excitingly, HTL0048149 (HTL'149), an orally available GPR52 agonist, has been advanced into phase I human clinical trials for the treatment of schizophrenia.
View Article and Find Full Text PDFDynamic Insights into the Self-Activation Pathway and Allosteric Regulation of the Orphan G-Protein-Coupled Receptor GPR52.
J Chem Inf Model
September 2023
Faculty of Environmental and Life Sciences, Beijing University of Technology, Beijing 100124, China.
Within over 800 members of G-protein-coupled receptors, there are numerous orphan receptors whose endogenous ligands are largely unknown, providing many opportunities for novel drug discovery. However, the lack of an in-depth understanding of the intrinsic working mechanism for orphan receptors severely limits the related rational drug design. The G-protein-coupled receptor 52 (GPR52) is a unique orphan receptor that constitutively increases cellular 5'-cyclic adenosine monophosphate (cAMP) levels without binding any exogenous agonists and has been identified as a promising therapeutic target for central nervous system disorders.
View Article and Find Full Text PDFThe Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders.
ACS Med Chem Lett
April 2023
Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom.
HTL0041178 (), a potent GPR52 agonist with a promising pharmacokinetic profile and exhibiting oral activity in preclinical models, has been identified. This molecule was the outcome of a judicious molecular property-based optimization approach, focusing on balancing potency against metabolic stability, solubility, permeability, and P-gp efflux.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!